A Case of Ethosuximide-Induced Aplastic Anemia Successfully Treated with Methylprednisolone Pulse Therapy.
10.15264/cpho.2018.25.2.175
- Author:
Hyun Sik KANG
1
;
Sun Hyung KIM
Author Information
1. Department of Pediatrics, Jeju National University Hospital, Jeju National University School of Medicine, Jeju, Korea. hyunsik.kang@jejunu.ac.kr
- Publication Type:Case Report
- Keywords:
Aplastic anemia;
Ethosuximide;
Methylprednisolone;
Anticonvulsants
- MeSH:
Anemia, Aplastic*;
Anticonvulsants;
Bone Marrow;
Bone Marrow Transplantation;
Child;
Diagnosis;
Environmental Exposure;
Epilepsy, Absence;
Ethosuximide;
Female;
Humans;
Methylprednisolone*;
Pancytopenia;
Parents;
Stem Cell Transplantation
- From:Clinical Pediatric Hematology-Oncology
2018;25(2):175-179
- CountryRepublic of Korea
- Language:English
-
Abstract:
Aplastic anemia may develop secondary to environmental exposure to entities such as chemicals, medical drugs, and infectious agents. Fatal complications from antiepileptic medications may occur despite careful and appropriate use. We report the case of a 9-year-old girl with a presenting diagnosis of aplastic anemia following treatment with ethosuximide for absence seizures. Aplastic anemia can now be cured with stem cell transplantation or immunosuppressive therapy. In this case, however, because of the impossibility of bone marrow transplantation and the specific needs of the patient's parents, three courses of methylprednisolone pulse therapy were administered. Following the therapy, there was improvement in pancytopenia and complete remission in the bone marrow. No adverse side effects of therapy were observed. The authors suggest that methylprednisolone pulse therapy may be a treatment for acquired aplastic anemia.
